Steglujan is owned by Merck Sharp Dohme.
Steglujan contains Ertugliflozin; Sitagliptin Phosphate.
Steglujan has a total of 7 drug patents out of which 2 drug patents have expired.
Expired drug patents of Steglujan are:
Steglujan was authorised for market use on 19 December, 2017.
Steglujan is available in tablet;oral dosage forms.
Steglujan can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The generics of Steglujan are possible to be released after 21 October, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(10 months ago) | |
US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
US8080580 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(4 months ago) | |
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
US9439901 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(7 years from now) | |
US9308204 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
27
United States
7
European Union
6
Korea, Republic of
6
Norway
5
EA
5
Israel
5
Denmark
5
Spain
5
Portugal
5
Germany
5
Georgia
5
China
4
Ecuador
4
Australia
4
Croatia
4
Canada
4
New Zealand
4
Costa Rica
4
Austria
4
ME
4
Cyprus
4
Ukraine
4
Poland
4
Japan
4
Hong Kong
4
Slovenia
4
Argentina
4
South Africa
3
Iceland
3
Dominican Republic
3
Netherlands
3
Peru
3
Malaysia
3
Morocco
3
Brazil
3
Mexico
3
Hungary
3
Taiwan
2
Colombia
2
AP
2
Luxembourg
2
IB
2
Yugoslavia
2
Tunisia
2
Jordan
2
RS
2
Lithuania
1
Panama
1
El Salvador
1
Honduras
1
Uruguay
1
Nicaragua
1
Chile
1
Bulgaria
1
Cuba
1
Belgium
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic